Avizafone (CAS 60067-15-4) is a high-purity, pharmaceutical-grade benzodiazepine prodrug synthesized via precise organic synthesis processes, fully complying with USP and EP quality standards. Its molecular structure is designed as a prodrug of diazepam, enabling rapid conversion to the active sedative compound in vivo—ensuring enhanced bioavailability and faster onset of action compared to traditional benzodiazepines. Produced with strict impurity control (≤0.1% total impurities), each batch undergoes potency verification, making it a reliable raw material for central nervous system (CNS) drug development.
This benzodiazepine prodrug excels in delivering rapid sedative, anxiolytic, and anticonvulsant effects, addressing the needs of pharmaceutical formulations for acute anxiety, seizure management, and preoperative sedation. Unlike direct benzodiazepine administration, its prodrug design reduces gastrointestinal irritation and improves patient tolerance, a key advantage for clinical applications. Its stable chemical properties also support long-term storage, making it suitable for large-scale pharmaceutical production.
Avizafone (CAS 60067-15-4) caters to diverse professional scenarios: from pharmaceutical manufacturers developing rapid-acting CNS medications to research institutions studying benzodiazepine prodrug mechanisms. Its high bioavailability, pharmaceutical-grade purity, and proven efficacy make it a top choice for buyers prioritizing performance and safety. Whether for commercial drug formulation or preclinical research, this benzodiazepine prodrug meets the rigorous demands of the pharmaceutical industry.
